Company intelligence / Profile preview

IntegerBio

Ownership: Private
Development stage: Commercial

Overview

IntegerBio is developing novel antiviral and anti-inflammatory therapeutics by leveraging advances at the intersection of immunology and virology. The company aims to create broad-spectrum solutions against multiple viruses by reimagining the potential of the innate immune system. No clinical results have been published as of early 2025.

Therapeutic areas: Infectious Diseases
Modalities: Small moleculeBiologicAntibody
Industry: Biotech

Partnerships

Not publicly disclosed as of January 2025.

Beyond the preview

Go deeper on IntegerBio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IntegerBio.

Explore the full profile